Health

As of Tuesday night, of the 755.4 million people who have received at least one shot of the Covid-19 vaccine in India, 380.7 million people are fully vaccinated (have received both shots) and another 374.7 million have received only one shot, according to data from the CoWIN dashboard. When seen alongside India’s estimated population of 940 million adults, this means that 40.3% of the country’s adults have been fully vaccinated while another 40.2% have been given a single jab so far.

NEW DELHI: Indicating “a low-level of Covid in India”, the Centers for Disease Control and Prevention (CDC) issued a Level-1 (lowest threat level) for the country, the US state department said.

The formulation has the medicinal herb Bergenia ciliata, which can help ease pain in rheumatoid arthritis

A day after World Health Organisation(WHO) granted emergency use approval for Bharat Biotech’s COVID-19 vaccine Covaxin, an official of the US Centers for Disease Control and Prevention (CDC) has informed that all travellers fully vaccinated against COVID-19 with Covaxin have been given the green light to enter the United States from November 8.

Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended its use in two doses, with a dose interval of four weeks, in all age groups 18 and above.

The Australian government on Monday gave recognition to Bharat Biotech’s Covaxin COVID-19 vaccine for the purpose of establishing a traveller’s vaccination status in the country.

India will produce over five billion doses of Covid vaccines for the country and the world by the end of 2022, Prime Minister Narendra Modi announced on Saturday at the G-20 Summit in Rome, where the grouping met to discuss, among other issues, developments related to the global pandemic.

India’s testing capacity has been ramped up extensively and it has conducted 60,58,85,769 COVID-19 tests so far, according to the Indian Council of Medical Research (ICMR) said on Friday.

In the new study, researchers at the National Institute of Mental Health and Neurological Sciences (NIMHANS), Bengaluru, and Institute of Genomics at the University of Tartu, Estonia, explored these aspects through the genetic analysis of individuals from families who have multiple affected members, considering that the increased prevalence of illness in a particular family should point to even more extreme evidence of the risky alleles.